Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The goal for the project is the identification and optimization of anti-viral compounds.
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
This work has been published in the journal ‘ACS applied materials and interface’
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
All India Institute of Ayurveda hosts ministers and showcase their achievements
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
